Literature DB >> 24725236

Therapy for hepatitis C--the costs of success.

Jay H Hoofnagle1, Averell H Sherker.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24725236     DOI: 10.1056/NEJMe1401508

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  49 in total

Review 1.  Ledipasvir with sofosbuvir.

Authors: 
Journal:  Aust Prescr       Date:  2015-10-14

Review 2.  Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

Review 3.  Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients.

Authors:  Mark W Hull; Eric M Yoshida; Julio S G Montaner
Journal:  Curr Infect Dis Rep       Date:  2016-07       Impact factor: 3.725

4.  Forecast for the Physician Payment Sunshine Act: partly to mostly cloudy?

Authors:  Stephanie R Morain; Charles Flexner; Nancy E Kass; Jeremy Sugarman
Journal:  Ann Intern Med       Date:  2014-12-16       Impact factor: 25.391

5.  Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.

Authors:  Thomas R O'Brien; Ruth M Pfeiffer; Ashley Paquin; Krystle A Lang Kuhs; Sabrina Chen; Herbert L Bonkovsky; Brian R Edlin; Charles D Howell; Gregory D Kirk; Mark H Kuniholm; Timothy R Morgan; Howard D Strickler; David L Thomas; Ludmila Prokunina-Olsson
Journal:  J Hepatol       Date:  2015-07-15       Impact factor: 25.083

6.  No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL.

Authors:  Thomas R O'Brien; Jordan J Feld; Shyam Kottilil; Ruth M Pfeiffer
Journal:  Hepatology       Date:  2015-11-25       Impact factor: 17.425

7.  Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease.

Authors:  Thomas Ward; Jason Gordon; Beverley Jones; Hayley Bennett; Samantha Webster; Anupama Kalsekar; Yong Yuan; Michael Brenner; Phil McEwan
Journal:  Clin Drug Investig       Date:  2017-01       Impact factor: 2.859

8.  A quasi-experimental evaluation of dried blood spot testing through community pharmacies in the Tayside region of Scotland.

Authors:  Andrew Radley; Karen Melville; Jan Tait; Brian Stephens; Josie M M Evans; John F Dillon
Journal:  Frontline Gastroenterol       Date:  2017-01-06

Review 9.  Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.

Authors:  Jagpreet Chhatwal; Tianhua He; Maria A Lopez-Olivo
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981

10.  The changing burden of hepatitis C virus infection in the United States: model-based predictions.

Authors:  Mina Kabiri; Alison B Jazwinski; Mark S Roberts; Andrew J Schaefer; Jagpreet Chhatwal
Journal:  Ann Intern Med       Date:  2014-08-05       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.